-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Editor of WuXi AppTec content team On January 3, 2022, Ovid Therapeutics announced that it has reached an exclusive license agreement with AstraZeneca to obtain AstraZeneca’s early development stage small molecule library targeting KCC2 transporters (including Lead drug candidate OV350)
.
Ovid Therapeutics seeks to optimize these KCC2 transporter activators and accelerate their development in epilepsy and other underlying neurological diseases
.
KCC2 is a potassium chloride cotransporter, responsible for maintaining the chloride homeostasis in neurons
.
KCC2 transporter is very important for seizure control
.
OV350 is a small molecule that directly targets and activates the KCC2 transporter, and has obtained encouraging in vitro and in vivo proofs of concept in drug-resistant epilepsy
.
By improving chloride homeostasis, OV350 can inhibit the overexcitement of neurons normally associated with epilepsy
.
Preclinical studies have shown that OV350 is well tolerated
.
OV350 may be developed to treat a variety of epilepsy and other central nervous system indications, including neurodevelopmental and neurodegenerative diseases
.
Image source: 123RF According to the terms of the agreement, AstraZeneca will receive an advance payment of 5 million U.
S.
dollars and Ovid stock worth 7.
5 million U.
S.
dollars, and will be eligible for potential clinical development and regulatory milestone payments of up to 53 million U.
S.
dollars
.
The total amount of the cooperation's commercial milestone payment can reach 150 million US dollars, and AstraZeneca also has the right to receive tiered royalties on future product net sales.
.
When the clinical efficacy is verified, AstraZeneca will have the priority to negotiate strategic cooperation
.
Dr.
Jeremy Levin, Chairman and CEO of Ovid, said: "KCC2 transporter is an exciting and novel target, and we believe it has great prospects in the treatment of epilepsy
.
" References: [1] Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators.
Retrieved January 3, 2021, from https://investors.
ovidrx.
com/news-releases/news-release-details/ovid-therapeutics-expands-epilepsy-franchise-novel-kcc2 The content team of Mingkangde focuses on introducing the global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
.
Ovid Therapeutics seeks to optimize these KCC2 transporter activators and accelerate their development in epilepsy and other underlying neurological diseases
.
KCC2 is a potassium chloride cotransporter, responsible for maintaining the chloride homeostasis in neurons
.
KCC2 transporter is very important for seizure control
.
OV350 is a small molecule that directly targets and activates the KCC2 transporter, and has obtained encouraging in vitro and in vivo proofs of concept in drug-resistant epilepsy
.
By improving chloride homeostasis, OV350 can inhibit the overexcitement of neurons normally associated with epilepsy
.
Preclinical studies have shown that OV350 is well tolerated
.
OV350 may be developed to treat a variety of epilepsy and other central nervous system indications, including neurodevelopmental and neurodegenerative diseases
.
Image source: 123RF According to the terms of the agreement, AstraZeneca will receive an advance payment of 5 million U.
S.
dollars and Ovid stock worth 7.
5 million U.
S.
dollars, and will be eligible for potential clinical development and regulatory milestone payments of up to 53 million U.
S.
dollars
.
The total amount of the cooperation's commercial milestone payment can reach 150 million US dollars, and AstraZeneca also has the right to receive tiered royalties on future product net sales.
.
When the clinical efficacy is verified, AstraZeneca will have the priority to negotiate strategic cooperation
.
Dr.
Jeremy Levin, Chairman and CEO of Ovid, said: "KCC2 transporter is an exciting and novel target, and we believe it has great prospects in the treatment of epilepsy
.
" References: [1] Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators.
Retrieved January 3, 2021, from https://investors.
ovidrx.
com/news-releases/news-release-details/ovid-therapeutics-expands-epilepsy-franchise-novel-kcc2 The content team of Mingkangde focuses on introducing the global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
